CELL & GENE MEETING ON THE MESA 2021 NEWS
Can cell therapies treat cardiovascular disease?
November 10, 2021 -- While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021.
November 10, 2021 -- While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021.
Opportunities for cell and gene therapy companies to partner with early investors
October 28, 2021 -- Cell and gene therapy firms are some of the hottest investment opportunities currently in the market, according to Chris Garabedian, CEO of Xontogeny and the portfolio manager of PXV Fund. Garabedian recently spoke with ScienceBoard.net about his investment strategy.
October 28, 2021 -- Cell and gene therapy firms are some of the hottest investment opportunities currently in the market, according to Chris Garabedian, CEO of Xontogeny and the portfolio manager of PXV Fund. Garabedian recently spoke with ScienceBoard.net about his investment strategy.
Clinical trial optimization in CGT can help make cardiovascular therapies a reality
October 25, 2021 -- ScienceBoard.net caught up with Dr. Monica Shah, who is vice president of medical strategy and head of the Cell and Gene Therapy (CGT) Center of Excellence at Iqvia, at Meeting on the Mesa. Shah moderated "Personalizing Cardiovascular Therapies to Address the Underlying Causes of Disease" on day two of the meeting.
October 25, 2021 -- ScienceBoard.net caught up with Dr. Monica Shah, who is vice president of medical strategy and head of the Cell and Gene Therapy (CGT) Center of Excellence at Iqvia, at Meeting on the Mesa. Shah moderated "Personalizing Cardiovascular Therapies to Address the Underlying Causes of Disease" on day two of the meeting.
Lessons learned help the cell and gene therapy industry deliver products to patients
October 22, 2021 -- On the second day of the Cell & Gene Meeting on the Mesa, Betty Woo, PhD, vice president and general manager of cell and gene therapy at Thermo Fisher Scientific, led a workshop titled "Industrialization of Cell Therapy Manufacturing -- Lessons Learned From Biologics." ScienceBoard.net caught up with Woo following the workshop.
October 22, 2021 -- On the second day of the Cell & Gene Meeting on the Mesa, Betty Woo, PhD, vice president and general manager of cell and gene therapy at Thermo Fisher Scientific, led a workshop titled "Industrialization of Cell Therapy Manufacturing -- Lessons Learned From Biologics." ScienceBoard.net caught up with Woo following the workshop.
How can the cell and gene therapy field industrialize collaboration?
October 21, 2021 -- Adlai Goldberg, the global life sciences digital, social, and commercial innovation leader at Ernst & Young, led a workshop on "Unlocking the Power of Collaboration to Fuel the Industry Transformation for Cell and Gene Therapies" at the 2021 Cell & Gene Meeting on the Mesa. Goldberg called on the cell and gene therapy industry to adopt a mindset of co-collaboration.
October 21, 2021 -- Adlai Goldberg, the global life sciences digital, social, and commercial innovation leader at Ernst & Young, led a workshop on "Unlocking the Power of Collaboration to Fuel the Industry Transformation for Cell and Gene Therapies" at the 2021 Cell & Gene Meeting on the Mesa. Goldberg called on the cell and gene therapy industry to adopt a mindset of co-collaboration.
5 takeaways from the Cell & Gene Meeting on the Mesa
October 21, 2021 -- In this final episode of our coverage from the 2021 Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, ScienceBoard.net Editor-in-Chief Samantha Black, PhD, discusses five takeaways from the event.
October 21, 2021 -- In this final episode of our coverage from the 2021 Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, ScienceBoard.net Editor-in-Chief Samantha Black, PhD, discusses five takeaways from the event.
Early engagement with regulatory agencies is key to therapeutic development
October 20, 2021 -- Next-generation advanced therapies call for novel regulatory approaches, according to Mark Lane, PhD, vice president, development consulting and scientific affairs, of Biopharma Excellence by PharmaLex. Lane moderated a panel discussion titled "Innovative Regulatory Pathways for Next-Generation Treatments" at the 2021 Cell & Gene Meeting on the Mesa.
October 20, 2021 -- Next-generation advanced therapies call for novel regulatory approaches, according to Mark Lane, PhD, vice president, development consulting and scientific affairs, of Biopharma Excellence by PharmaLex. Lane moderated a panel discussion titled "Innovative Regulatory Pathways for Next-Generation Treatments" at the 2021 Cell & Gene Meeting on the Mesa.
Cardiovascular cell, gene therapy leaders discuss nascent field
October 18, 2021 -- The emerging field of cardiovascular cell and gene therapies shows great promise to significantly improve clinical outcomes, but it still faces key challenges, according to an October 13 plenary session at the Cell & Gene Meeting on the Mesa.
October 18, 2021 -- The emerging field of cardiovascular cell and gene therapies shows great promise to significantly improve clinical outcomes, but it still faces key challenges, according to an October 13 plenary session at the Cell & Gene Meeting on the Mesa.
CGTBO editor comments on trends from Cell & Gene Meeting on the Mesa
October 18, 2021 -- Blake Middleton, editor of Cell & Gene Therapy Business Outlook (CGTBO), was joined by Bruce Carlson, senior vice president of publications at Science and Medicine Group, to review the latest developments in therapies from the 2021 Cell & Gene Meeting on Mesa.
October 18, 2021 -- Blake Middleton, editor of Cell & Gene Therapy Business Outlook (CGTBO), was joined by Bruce Carlson, senior vice president of publications at Science and Medicine Group, to review the latest developments in therapies from the 2021 Cell & Gene Meeting on Mesa.
Opportunities abound in cell and gene therapy for discerning investors
October 14, 2021 -- CARLSBAD, CA - There are more opportunities in the cell and gene therapy sector than ever before. But to profit from them, investors must be more discerning than in the past, according to a panel of investors at the Cell & Gene Meeting on the Mesa on October 14.
October 14, 2021 -- CARLSBAD, CA - There are more opportunities in the cell and gene therapy sector than ever before. But to profit from them, investors must be more discerning than in the past, according to a panel of investors at the Cell & Gene Meeting on the Mesa on October 14.
Cell & Gene Meeting on the Mesa 2021 Industry News
Regenerative medicine: Disrupting the status quo in 2021
April 1, 2022 -- Regenerative medicine is taking aim at cancer and a wide range of other prevalent and rare diseases, according to the 2021 annual report of the Alliance for Regenerative Medicine. Read More
AGTC CEO to present at Cell & Gene Meeting on the Mesa
October 12, 2021 -- Biotechnology firm Applied Genetic Technologies (AGTC) President and CEO Sue Washer will present at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, on October 13 at 11:15 a.m. PT. Read More
Tenaya Therapeutics CEO to present at Cell & Gene Meeting
October 12, 2021 -- Faraz Ali, CEO of biotechnology firm Tenaya Therapeutics, will present on October 13 at 3:15 p.m. PT as part of a panel discussion at the Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Forge Biologics to present at Cell & Gene Meeting on the Mesa
October 11, 2021 -- Forge Biologics will deliver a presentation about its adeno-associated virus gene therapy at the upcoming Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Artisan Bio to highlight CRISPR platform at Cell & Gene Meeting
October 11, 2021 -- Artisan Bio plans to highlight its CRISPR-engineered cell therapy platform at the Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
GenSight Biologics to highlight gene therapies at Cell & Gene Meeting
October 11, 2021 -- French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
ViaCyte CEO to present at Cell & Gene Meeting
October 8, 2021 -- ViaCyte will present data on the latest product candidates the company is developing to treat type 1 diabetes at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14 at 10:15 a.m. PST. Read More
Rocket Pharmaceuticals CEO to present at Cell & Gene Meeting
October 8, 2021 -- Dr. Gaurav Shah, chief executive officer of Rocket Pharmaceuticals, will present in person at the 2021 Cell & Gene Meeting on the Mesa on Tuesday, October 12, at 2:15 p.m. PST. Read More
Brainstorm EVP to give presentation at Cell & Gene Meeting
October 8, 2021 -- Stacy Lindborg, PhD, executive vice president and head of global clinical research at BrainStorm Cell Therapeutics, will deliver a presentation at the 2021 Cell & Gene Meeting on the Mesa, held October 12-14 in Carlsbad, CA, and virtually October 19-20. Read More
Aruvant presenting at Cell & Gene Meeting
October 8, 2021 -- The leadership team for Aruvant Sciences will participate in the annual Cell & Gene Meeting on the Mesa in person in Carlsbad, CA, and online from October 12-14. Read More
Industry News